• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Kezar Life Sciences Inc (NQ: KZR )

    7.370 -0.040 (-0.54%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Kezar Life Sciences Inc

    < Previous 1 2 3 4 5 6 7 Next >
    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
    From Kezar Life Science
    Via Business Wire
    Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Wells Fargo Beefs Up Kezar Life Price Target - Read Why
    Via Benzinga
    Kezar Life Sciences (KZR) Stock Soars on Lupus Trial Results
    KZR stock is soaring today on news that Kezar Life Sciences' Lupus treatment showed positive results in a clinical trial. 
    Via InvestorPlace
    Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating
    The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81. 
    Via Investor's Business Daily
    Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Kezar Life Sciences, Inc.
    Via Business Wire
    The Week In Charts: How To Make Money While Waiting For Core Trend Trades
    The real money is in the longer-term core trend trades. However, sometimes those opportunities can be few and far between. This is especially true in a bear market. 
    Via Talk Markets
    Biotech ETF Tops in June: 5 Stocks That Outperform
    Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%. 
    Via Talk Markets
    Short Volatility Alert: Kezar Life Sciences, Inc.
    On Tuesday, shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) experienced volatile short activity. After the activity, the stock price went up +43.43% to $8.29. The overall sentiment for KZR has been... 
    Via Benzinga
    InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday
    Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade. 
    Via Benzinga
    Dow Dips Over 400 Points; Crude Oil Rises 2%
    U.S. stocks turned sharply lower toward the end of trading, with the Dow Jones dropping more than 400 points on Tuesday. 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Gainers 
    Via Benzinga
    Nasdaq Turns Lower; Kezar Life Sciences Shares Jump
    U.S. stocks pared gains midway through trading, with the Nasdaq Composite and S&P 500 turning lower on Tuesday. 
    Via Benzinga
    Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session
    Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade. 
    Via Benzinga
    Occidental Petroleum (OXY) Stock Gets Boost From Yet Another Buffett Buy
    Occidental Petroleum (OXY) stock is rising on Tuesday after Warren Buffett's Berkshire Hathaway increased its stake in the company. 
    Via InvestorPlace
    Markets Open Higher; US Goods Gap Narrows To $104.3B In May
    U.S. stocks traded higher this morning, with the Dow Jones gaining over 350 points on Tuesday. 
    Via Benzinga
    Why Kezar Life Sciences Stock Is Soaring Today
    Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging Tuesday after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib. 
    Via Benzinga
    The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Good morning! It's time for another dive into the biggest pre-market stock movers as we go over the news for Tuesday morning! 
    Via InvestorPlace
    Why Is Kezar Life Sciences Surging By 78%? 25 Stocks Moving In Tuesday's Pre-Market Session
    Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Gainers 
    Via Benzinga
    Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate
    Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN). 
    Via Benzinga
    After-Hours Action: Why Kezar Life Sciences Stock Is Soaring
    Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging in Monday's after-hours session after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib. 
    Via Benzinga
    Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
    From Kezar Life Sciences, Inc.
    Via Business Wire
    Billionaire Israel Englander Is Betting Big on These 5 Stocks
    Millennium Management's Israel Englander is in focus after the billionaire's fund purchased several stocks this month. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.